Unlike Nutrien (NTR), Mosaic (MOS), and CF Industries (CF), Monsanto (MON) is overshadowed by its pending merger with Bayer. The merger is pending approval from antitrust watchdogs in certain jurisdictions. On March 14, Bayer indicated that it received positive support from Russia, according to Reuters.
Given the anticipation of the merger with Bayer, there isn’t much action on Monsanto’s ratings and target price.
The current consensus mean rating on Monsanto stands at 2.6 with an overall “hold” recommendation on the stock. Out of the 18 analysts in the above chart, ~11% or two analysts have a “strong buy” recommendation on the stock for the next 12-month period. About 22% or four analysts have a “buy” recommendation on the stock for the same period, while 67% or 12 analysts have a “hold” recommendation for Monsanto.
The consensus mean target price on Monsanto for the next 12-month period stood at $125.8. Bayer’s acquisition price is $128, which is also analysts’ current median target price on the stock. The current mean and median target price would give ~2.1% and 3.9% upside over the market closing price of $123.15 on March 14.